Wednesday, February 8, 2012

Illumina Says Roche's Offer is "Grossly Inadequate"

Illumina’s Board Unanimously Rejects Roche’s Unsolicited Tender Offer as Inadequate

I'm not tendering any of our remaining ILMN shares. Illumina says, "the $44.50 per share cash offer is grossly inadequate in multiple respects, dramatically undervalues Illumina and is contrary to the best interests of Illumina’s stockholders."

ILMN closed yesterday (02012.02.07) at $51.80. 52-week range: $25.57 - $79.40

1 comment:

  1. I didn't notice that Illumina reported 4Q'11 results after the market closed yesterday (02012.02.07). A couple of items from the press release.

    (1) "Record cash flow from operations of $108 million and record free cash flow of $81 million for the quarter."

    (2) "The company ended the fourth quarter of 2011 with $1.2 billion in cash, cash equivalents and short-term investments compared to $894.3 million as of January 2, 2011."

    (3) The company gave financial outlook and guidance for 02012.

    ReplyDelete